We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

66 hedge funds and large institutions have $15.3M invested in NeuBase Therapeutics, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 14 increasing their positions, 20 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 14

3% more funds holding

Funds holding: 64 → 66 (+2)

17% less capital invested

Capital invested by funds: $18.4M → $15.3M (-$3.15M)

30% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 20

90% less call options, than puts

Call options by funds: $40K | Put options by funds: $397K

Holders
66
Holders Change
+2
Holders Change %
+3.13%
% of All Funds
1.78%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
14
Reduced
20
Closed
14
Calls
$40K
Puts
$397K
Net Calls
-$357K
Net Calls Change
-$2.04M

Top Buyers

1
TI
Turner Investments
Pennsylvania
+$671K
2
AllianceBernstein
AllianceBernstein
Tennessee
+$598K
3
Goldman Sachs
Goldman Sachs
New York
+$156K
4
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
+$126K
5
HighTower Advisors
HighTower Advisors
Illinois
+$108K

Top Sellers

1
BFA
BlackRock Fund Advisors
California
-$1.44M
2
State Street
State Street
Massachusetts
-$661K
3
SFM
Sphera Funds Management
Israel
-$476K
4
BIT
BlackRock Institutional Trust
California
-$462K
5
DBG
De Burlo Group
Massachusetts
-$399K
Name Holding Trade Value Shares
Change 		Change in
Stake
HighTower Advisors
26
HighTower Advisors
Illinois
$100K +$108K +100 New
PP
27
Paloma Partners
Connecticut
$99K +$107K +99 New
Morgan Stanley
28
Morgan Stanley
New York
$90K -$63.6K -59 -40%
VKH
29
Virtu KCG Holdings
New York
$90K +$44.2K +41 +85%
UBS Group
30
UBS Group
Switzerland
$82K -$18.3K -17 -17%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$79K -$161K -149 -66%
CS
32
Credit Suisse
Switzerland
$77K +$9.71K +9 +13%
CCA
33
Catalyst Capital Advisors
New York
$75K – – –
Deutsche Bank
34
Deutsche Bank
Germany
$66K +$6.47K +6 +10%
Group One Trading
35
Group One Trading
Illinois
$65K -$46.4K -43 -40%
BIC
36
Beach Investment Counsel
Pennsylvania
$64K – – –
WMC
37
Westwood Management Corporation
Illinois
$50K – – –
Balyasny Asset Management
38
Balyasny Asset Management
Illinois
$49K +$52.8K +49 New
BIT
39
BlackRock Institutional Trust
California
$48K -$462K -428 -90%
AGM
40
Alpine Global Management
New York
$46K +$48.5K +45 New
PPCM
41
Pillar Pacific Capital Management
California
$44K – – –
Citadel Advisors
42
Citadel Advisors
Florida
$40K -$1.08K -1 -2%
AQR Capital Management
43
AQR Capital Management
Connecticut
$33K – – –
Squarepoint
44
Squarepoint
New York
$33K +$35.6K +33 New
DBG
45
De Burlo Group
Massachusetts
$32K -$399K -370 -92%
LP
46
LMR Partners
United Kingdom
$30K +$32.3K +30 New
SFM
47
Soros Fund Management
New York
$30K +$32.3K +30 New
BRWA
48
B. Riley Wealth Advisors
Florida
$29K – – –
T. Rowe Price Associates
49
T. Rowe Price Associates
Maryland
$29K – – –
State Street
50
State Street
Massachusetts
$28K -$661K -613 -96%
1
2
3 4

NBSE Hedge Fund Activity: Q2 2015 in Review

66 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2015, worth a combined $15.3M — down 17% from $18.4M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new NBSE positions and 14 closed out — a net gain of 2 holders — while 14 added to existing stakes and 20 trimmed.

The largest buyer was Turner Investments, adding an estimated $671K. The largest seller was BlackRock Fund Advisors, cutting an estimated $1.44M.

  • 66 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2015, up from 64 in Q1 2015.
  • Funds reported $15.3M of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2015, down 17% quarter-over-quarter.
  • 16 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2015 and 14 closed out, a net change of +2 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q2 2015 was Turner Investments, an estimated $671K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q2 2015 was BlackRock Fund Advisors, an estimated $1.44M sold.

Based on aggregated 13F filings for Q2 2015.